• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Med. & Reg. Officer Ingenito Gary exercised 225,000 shares at a strike of $2.24 and sold $4,894,610 worth of shares (225,000 units at $21.75) (SEC Form 4)

    3/7/25 5:00:21 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    INGENITO GARY

    (Last) (First) (Middle)
    355 ALHAMBRA CIRCLE, SUITE 801

    (Street)
    CORAL GABLES FL 33134

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CATALYST PHARMACEUTICALS, INC. [ CPRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Med. & Reg. Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common stock, par value $0.001 per share 03/05/2025 M 44,904 A $2.24 113,777 D
    Common stock, par value $0.001 per share 03/05/2025 S 44,904(1) D $22.09(2) 68,873 D
    Common stock, par value $0.001 per share 03/06/2025 M 180,096 A $2.24 248,969 D
    Common stock, par value $0.001 per share 03/06/2025 S 180,096(1) D $21.67(3) 68,873 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Options to purchase common stock $2.24 03/05/2025 M 44,904 (4) 12/19/2025 Common Stock 44,904 $0 970,378 D
    Options to purchase common stock $2.24 03/06/2025 M 180,096 (4) 12/19/2025 Common Stock 180,096 $0 790,282 D
    Explanation of Responses:
    1. Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
    2. Represents a weighted average price for the shares sold. Shares were sold in a range between $22.00 and $22.285 per share.
    3. Represents a weighted average price for the shares sold. Shares were sold in a range between $21.60 and $21.95 per share.
    4. Options vested in three annual tranches beginning on December 19, 2019.
    /s/ Gary Ingenito 03/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPRX

    DatePrice TargetRatingAnalyst
    2/4/2025$28.00Outperform
    Robert W. Baird
    11/18/2024$35.00Overweight
    Stephens
    3/14/2024$27.00Buy
    Citigroup
    3/7/2024$23.00Buy
    BofA Securities
    12/21/2023$30.00Outperform
    Oppenheimer
    8/24/2022$10.00 → $15.50Buy → Neutral
    ROTH Capital
    2/8/2022$9.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Catalyst Pharma with a new price target

      Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00

      2/4/25 7:01:07 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Catalyst Pharma with a new price target

      Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00

      11/18/24 8:40:25 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Catalyst Pharma with a new price target

      Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00

      3/14/24 7:36:28 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care